کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8770016 | 1598218 | 2018 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Dabigatran Reversal in a Patient With End-Stage Liver Disease and Acute Kidney Injury
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
dabigatran - دابیگاتران acute kidney injury (AKI) - آسیب حاد کلیه (AKI)Idarucizumab - ایدارویزومابDrug safety - ایمنی مواد مخدرdose adjustment - تنظیم دوزHemorrhage - خونریزیBleeding - خونریزیoral anticoagulant - ضد انعقاد خوراکیthrombin inhibitor - مهار کننده ترومبینdecreased kidney function - کاهش عملکرد کلیهrenal clearance - کلیه
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
بیماریهای کلیوی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Dabigatran, a direct thrombin inhibitor and one of the new class of direct oral anticoagulants, is increasingly used in preference to warfarin because of its efficacy and ease of administration. However, because the drug is cleared by the kidneys, it can accumulate in plasma and increase the risk for bleeding in patients with decreased kidney function. We report a patient with end-stage liver disease who developed life-threatening hemorrhage and acute kidney injury while taking dabigatran, 150Â mg, twice daily. Although the patient received idarucizumab, an anti-dabigatran antibody fragment used as an antidote, hemostasis could not be achieved. Administration of vitamin K, fresh frozen plasma, desmopressin, octreotide, and pantoprazole did not arrest bleeding or affect coagulation parameters, and it was not possible to establish vascular access for hemodialysis. In patients with end-stage liver disease, who are at increased risk for both bleeding and acute kidney injury, dabigatran should be prescribed cautiously and at decreased dose.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: American Journal of Kidney Diseases - Volume 71, Issue 1, January 2018, Pages 137-141
Journal: American Journal of Kidney Diseases - Volume 71, Issue 1, January 2018, Pages 137-141
نویسندگان
James E. Novak, Khalid Alamiri, Jerry Yee,